Scientific Evidence

Integrating the melanoma 31-gene expression profile test with surgical oncology practice within national guideline and staging recommendations

Oct 2020

Define changes in clinical management resulting from the use of the prognostic 31-gene expression profile (31-GEP) test for cutaneous melanoma in a surgical oncology practice.

Author: Hyams D, et al.

Publication: Future Oncology

Integration of a 31-gene expression profile into clinical decision-making in the treatment of cutaneous melanoma

Aug 2020

Retrospective review and early experience in utilizing 31-GEP in intermediate melanomas and its effect on clinical management.

Author: Scott A, et al.

Publication: The American Surgeon

Clinical validity of a gene expression signature in diagnostically uncertain neoplasms

Jun 2020

A retrospective study demonstrating high diagnostic accuracy of the 23-GEP in diagnostically uncertain cases when evaluated against clinical outcomes.

Author: Clarke L, et al.

Publication: Personalized Medicine

A systematic review and meta-analysis of gene expression profiling for primary cutaneous melanoma prognosis

May 2020

Systematic review of available evidence on GEP for prognosis. Included meta-analysis of 6 studies on the 31-GEP. Clinical implications show that 31-GEP can better assess prognosis leading to more appropriate patient management.

Author: Litchman GH, et al.

Publication: SKIN: Journal of Cutaneous Melanoma

Molecular risk prediction in cutaneous melanoma: a meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients

Mar 2020

Meta-analysis stage I-II patients. GEP consistently identifies melanoma patients at increased risk of metastasis, independent of clinicopathologic features and can be used in conjunction with traditional staging to improve patient risk stratification.

Author: Greenhaw B, et al.

Publication: Journal of the American Academy of Dermatology

Appropriate use criteria for the integration of diagnostic and prognostic gene expression profile assays into the management of cutaneous malignant melanoma: an expert panel consensus-based modified delphi process assessment

Sep 2019

Expert panel of 9 dermatologists developed 29 clinical scenarios creating an evidence based framework for AUC recommendations for integration of melanoma GEP tests into clincial practice.

Author: Berman B, et al.

Publication: SKIN: Journal of Cutaneous Melanoma

Level of evidence review for a gene expression profile test for cutaneous melanoma

Jul 2019

Review the current literature and establish the level of evidence for a cutaneous melanoma 31-GEP test.

Author: Dubin DP, et al.

Publication: American Journal of Clinical Dermatology

Establishing an evidence-based decision point for clinical use of the 31-gene expression profile test in cutaneous melanoma

Jul 2019

Multi center study establishing appropriate use criteria for determining risk of recurrence in patients with tumors >0.3mm in thickness.

Author: Marks E, et al.

Publication: SKIN: Journal of Cutaneous Melanoma

Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma

Apr 2019

Independent, prospective study with over 3.5 years of follow-up, showing results consistent with previous validation studies with GEP class score as statistically associated with MSS, DMFS and RFS.

Author: Keller J, et al.

Publication: Cancer Medicine

Correlation of melanoma gene expression score with clinical outcomes on a series of melanocytic lesions

Apr 2019

Clinical validation study of the 23-GEP in lesions with clinical outcomes and follow-up data.

Author: Ko J, et al.

Publication: Human Pathology

Early outcome of a 31-gene expression profile test in 86 AJCC stage IB-II melanoma patients

Jan 2019

A prospective multicentre cohort study.  Multicentre evaluation the early prognostic performance of a genetic signature in a multicentre prospectively evaluated cohort.

Author: Podlipnik S, et al.

Publication: Journal of the European Academy of Dermatology and Venereology

Performance of a 31-gene expression profile test in cutaneous melanomas of the head and neck

Jan 2019

Gene expression profile class and node status stratified tumors into significantly different 5-year survival groups by Kaplan-Meier method and both were independent predictors of recurrence in multivariate analysis.

Author: Gastman B, et al.

Publication: Head and Neck